Amylyx Pharmaceuticals
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
43 Thorndike St, Cambridge, Massachusett...Phone Number
(617) 682-0917Website
www.amylyx.comRevenue
-Stock Symbol
AMLXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
6
1
1
1
1
1
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease and other neurodegenerative diseases. The company's therapeutic, AMX0035, targets the neuroinflammation and nerve cell death that characterize these diseases. AMX0035 is a proprietary combination of existing compounds that act synergistically to prevent cell death and neurotoxic inflammation in multiple preclinical models.Explore more
Amylyx Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Amylyx Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Amylyx Pharmaceuticals launches new products
Congratulate Masked Content for being promoted to Masked Content at Amylyx Pharmaceuticals
Funding: Get notified immidiatlly once Amylyx Pharmaceuticals has new funding data
Earning: See what the market has to say on Amylyx Pharmaceuticals recently announced quarterly report
Check out if Amylyx Pharmaceuticals is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Amylyx Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Amylyx Pharmaceuticals had a recent Job posting/layoffs
Check if Amylyx Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Amylyx Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to Amylyx Pharmaceuticals
Compare insights from companies similar to Amylyx Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Amylyx Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Amylyx Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Amylyx Pharmaceuticals.
Amylyx Pharmaceuticals financials insights
Gather financial insights about Amylyx Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Grant
$3M
Series A
$5M
2017
Debt
$1.8M
2019
Debt
$937K
2020
Debt
$150K
Series B
$30M
2021
Series C
$135M
2022
Stock Offering
$190M
2025
Stock/Share Issuance
$175M
Amylyx Pharmaceuticals Tech Stack
A closer look at the technologies used by Amylyx Pharmaceuticals
Most Recent Scoops
Open Position
Open Position
Person-Based
Medical Research, Clinical Operations
Open Position
Open Position
Amylyx Pharmaceuticals News & Media
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 10, 2026 10:40 AM EDTCompany ParticipantsJustin Klee -...Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Amylyx Pharmaceuticals, Inc. – AMLX
BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the District of Massachusetts has approved the following announcement of a proposed class action settlement that would benefit purchasers of publicly traded securities of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX):Amylyx Stock: Why the Full Pipeline Story Matters
Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX sharesAmylyx Pharmaceuticals, Inc. (AMLX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Bank of America Global Healthcare Conference 2026 May 13, 2026 4:40 PM EDTCompany ParticipantsJoshua Cohen - Co-Founder,...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Amylyx Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease and other neurodegenerative diseases. The company's therapeutic, AMX0035, targets the neuroinflammation and nerve cell death that characterize these diseases. AMX0035 is a proprietary co... Read More
